Your browser doesn't support javascript.
Recommendations for detection, prioritization, and treatment of thoracic oncology patients during the COVID-19 pandemic: the THOCOoP cooperative group.
Arrieta, Oscar; Cardona, Andrés F; Lara-Mejía, Luis; Heredia, David; Barrón, Feliciano; Zatarain-Barrón, Zyanya Lucia; Lozano, Francisco; de Lima, Vladmir Cordeiro; Maldonado, Federico; Corona-Cruz, Francisco; Ramos, Maritza; Cabrera, Luis; Martin, Claudio; Corrales, Luis; Cuello, Mauricio; Arroyo-Hernández, Marisol; Aman, Enrique; Bacon, Ludwing; Baez, Renata; Benitez, Sergio; Botero, Antonio; Burotto, Mauricio; Caglevic, Christian; Ferraris, Gustavo; Freitas, Helano; Kaen, Diego Lucas; Lamot, Sebastián; Lyons, Gustavo; Mas, Luis; Mata, Andrea; Mathias, Clarissa; Muñoz, Alvaro; Patane, Ana Karina; Oblitas, George; Pino, Luis; Raez, Luis E; Remon, Jordi; Rojas, Leonardo; Rolfo, Christian; Ruiz-Patiño, Alejandro; Samtani, Suraj; Viola, Lucia; Viteri, Santiago; Rosell, Rafael.
  • Arrieta O; Instituto Nacional de Cancerología, Mexico City, Mexico. Electronic address: oscararrietaincan@gmail.com.
  • Cardona AF; Thoracic Oncology Clinic, Clínica del Country, Bogotá, Colombia; Foundation for Clinical and Applied Cancer Research, Bogotá, Colombia.
  • Lara-Mejía L; Instituto Nacional de Cancerología, Mexico City, Mexico.
  • Heredia D; Instituto Nacional de Cancerología, Mexico City, Mexico.
  • Barrón F; Instituto Nacional de Cancerología, Mexico City, Mexico.
  • Zatarain-Barrón ZL; Instituto Nacional de Cancerología, Mexico City, Mexico.
  • Lozano F; Instituto Nacional de Cancerología, Mexico City, Mexico.
  • de Lima VC; Departamento de Oncologia Clínica - A C Camargo Cancer Center, São Paulo, Brazil.
  • Maldonado F; Instituto Nacional de Cancerología, Mexico City, Mexico.
  • Corona-Cruz F; Instituto Nacional de Cancerología, Mexico City, Mexico.
  • Ramos M; Instituto Nacional de Cancerología, Mexico City, Mexico.
  • Cabrera L; Instituto Nacional de Cancerología, Mexico City, Mexico.
  • Martin C; Thoracic Oncology Unit, Alexander Fleming Institute, Buenos Aires, Argentina; Hospital Maria Ferrer, Buenos Aires, Argentina.
  • Corrales L; Oncology Department, Hospital San Juan de Dios, San José Costa Rica, Costa Rica; Oncología Médica, Centro de Investigación y Manejo del Cáncer (CIMCA), San José, Costa Rica.
  • Cuello M; Department of Oncology, Hospital de Clínicas, Universidad de la República - UDELAR, Montevideo, Uruguay.
  • Arroyo-Hernández M; Instituto Nacional de Cancerología, Mexico City, Mexico.
  • Aman E; Clinical Oncology Unit, Swiss Medical Group, Buenos Aires, Argentina.
  • Bacon L; Centro de Oncología, Hospital Vivián Pellas, Nicaragua.
  • Baez R; National Institute for Respiratory Diseases, Mexico City, Mexico.
  • Benitez S; Coordinador de la sección Oncología, asociación Argentina de Medicina Respiratoria, Argentina.
  • Botero A; Hospital La Católica Goicoechea, San José, Costa Rica.
  • Burotto M; Clínica Universidad de los Andes, Centro de Estudios Clínicos Bradford Hill, Chile.
  • Caglevic C; Departamento de Investigación del Cáncer- Fundación Arturo López Pérez, Santiago, Chile.
  • Ferraris G; Centro Médico Dean Funes, Radioterapia Oncológica, Córdoba, Argentina.
  • Freitas H; Departamento de Oncologia Clínica - A C Camargo Cancer Center, São Paulo, Brazil.
  • Kaen DL; Centro Oncológico Riojano Integral, La Rioja, Argentina.
  • Lamot S; CONCIENCIA, Instituto Oncohematológico de la Patagonia, Chile.
  • Lyons G; Department of Thoracic Surgery, Hospital Británico, Buenos Aires, Argentina.
  • Mas L; Medical Oncology Department, National Institute for Neoplastic Diseases - INEN, Lima, Peru.
  • Mata A; Hospital La Católica Goicoechea, San José, Costa Rica.
  • Mathias C; NOB/Oncoclínicas, Salvador BA, Brazil.
  • Muñoz A; Fundación Santa Fe de Bogotá, Bogotá, Colombia.
  • Patane AK; Hospital de Rehabilitacion Respiratoria María Ferrer, Buenos Aires, Argentina.
  • Oblitas G; Unidad Oncológica Molecular Peruana, Lima, Perú.
  • Pino L; Medical Oncology Group, Fundación Santa Fe de Bogotá, Bogotá, Colombia.
  • Raez LE; Thoracic Oncology Program Memorial Cancer Institute, Memorial Healthcare System, Pembroke Pines, FL, United States.
  • Remon J; Medical Oncology Department, Centro Integral Oncología Clara Campal Bacelona, HM-Delfos, Barcelona, Spain.
  • Rojas L; Medical Oncology Department, Clínica Colsanitas, Bogotá, Colombia.
  • Rolfo C; Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, Maryland, United States.
  • Ruiz-Patiño A; Foundation for Clinical and Applied Cancer Research, Bogotá, Colombia.
  • Samtani S; Medical Oncology Department, Clínica Bradford Hill, Santiago, Chile.
  • Viola L; Fundación neumológica colombiana, Bogotá, Colombia.
  • Viteri S; Instituto Oncológico Dr. Rosell. Centro Médico Teknon. Grupo QuironSalud. Barcelona, España.
  • Rosell R; Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain.
Crit Rev Oncol Hematol ; 153: 103033, 2020 Sep.
Article in English | MEDLINE | ID: covidwho-611931
Semantic information from SemMedBD (by NLM)
1. Detection TREATS Patients
Subject
Detection
Predicate
TREATS
Object
Patients
2. Malignant neoplasm of lung PROCESS_OF Patients
Subject
Malignant neoplasm of lung
Predicate
PROCESS_OF
Object
Patients
3. Poor outcome PROCESS_OF Patients
Subject
Poor outcome
Predicate
PROCESS_OF
Object
Patients
4. Detection TREATS Patients
Subject
Detection
Predicate
TREATS
Object
Patients
5. Malignant neoplasm of lung PROCESS_OF Patients
Subject
Malignant neoplasm of lung
Predicate
PROCESS_OF
Object
Patients
6. Poor outcome PROCESS_OF Patients
Subject
Poor outcome
Predicate
PROCESS_OF
Object
Patients
ABSTRACT
The world currently faces a pandemic due to SARS-CoV-2. Relevant information has emerged regarding the higher risk of poor outcomes in lung cancer patients. As such, lung cancer patients must be prioritized in terms of prevention, detection and treatment. On May 7th, 45 experts in thoracic cancers from 11 different countries were invited to participate. A core panel of experts regarding thoracic oncology care amidst the pandemic gathered virtually, and a total of 60 initial recommendations were drafted based on available evidence, 2 questions were deleted due to conflicting evidence. By May 16th, 44 experts had agreed to participate, and voted on each of the 58 recommendation using a Delphi panel on a live voting event. Consensus was reached regarding the recommendations (>66 % strongly agree/agree) for 56 questions. Strong consensus (>80 % strongly agree/agree) was reached for 44 questions. Patients with lung cancer represent a particularly vulnerable population during this time. Special care must be taken to maintain treatment while avoiding exposure.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Main subject: Pneumonia, Viral / Thoracic Neoplasms / Coronavirus Infections / Coronavirus / Pandemics / Patient Care Subject: Pneumonia, Viral / Thoracic Neoplasms / Coronavirus Infections / Coronavirus / Pandemics / Patient Care Type of study: Broad_synthesis / Diagnostic study / Clinical Practice Guide Language: English Journal: Crit Rev Oncol Hematol Clinical aspect: Etiology Year: 2020

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Document Type: Article Main subject: Pneumonia, Viral / Thoracic Neoplasms / Coronavirus Infections / Coronavirus / Pandemics / Patient Care Subject: Pneumonia, Viral / Thoracic Neoplasms / Coronavirus Infections / Coronavirus / Pandemics / Patient Care Type of study: Broad_synthesis / Diagnostic study / Clinical Practice Guide Language: English Journal: Crit Rev Oncol Hematol Clinical aspect: Etiology Year: 2020
...